Company intelligence / Profile preview

Enlyton

Columbus, Ohio, United Statesleadiq.com ↗

Ownership: Private
Development stage: Other

Overview

Enlyton has developed a proprietary monoclonal antibody platform targeting TAG‑72, highly expressed in many solid tumors. Their lead program ENL210 is designed to improve cancer imaging and intraoperative detection. The company has completed preclinical research and is preparing for GMP manufacturing, toxicology studies, IND submission, and initial clinical trials. No published clinical results yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody (general)Small molecule (possible, but primary focus is antibodies)
Industry: Protein Biomarker Diagnostics

Partnerships

ViroMed Co., Ltd. (now Helixmith): licensing agreement for humanized mAb 3E8 targeting TAG‑72 antigen for cancer detection/drug deliveryEast Sunshine Foresight Fund/HEC Pharm (investment partnership to advance development of ENL210)

Beyond the preview

Go deeper on Enlyton.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enlyton.

Explore the full profile